Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors

Sanjeev Kaul, Linus N. Igwemezie, David J. Stewart, Scott Z. Fields, Michael Kosty, Nathan Levithan, Ronald Bukowski, David Gandara, Glenwood Goss, Peter O'Dwyer, Lee P. Schacter, Rashmi H. Barbhaiya

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Purpose: To assess the pharmacokinetics and bioequivalence of etoposide following intravenous (IV) administration of etoposide phosphate (Etopophos; Bristol-Myers Squibb, Princeton, NJ), a prodrug of etoposide, and VePesid (Bristol-Myers Squibb). Patients and Methods: Forty-nine solid tumor patients were randomized to receive Etopophos or VePesid on day 1 of a day-1,3,5 schedule of treatment. The alternate drug was given on day 3 and repeated on day 5. The dose, 150 mg/m2 of etoposide equivalent, was administered by constant rate infusion over 3.5 hours. The plasma concentrations of etoposide phosphate and etoposide were determined using validated high-performance liquid chromatography (HPLC) assays. Pharmacokinetic parameters were calculated by a noncompartmental method. Etopophos was considered ta be bioequivalent to VePesid if the 90% confidence limits for the differences in mean maximum concentration (C(max)) and AUC(inf) of etoposide were contained within 80% to 125% for the log-transformed data. Results: Forty-one patients were assessable for pharmacokinetics and bioequivalence assessment. Following IV administration, etoposide phosphate was rapidly and extensively converted to etoposide in systemic circulation, resulting in insufficient data to estimate its pharmacokinetics. The mean bioavailability of etoposide from Etopophos, relative to VePesid, was 103% (90% confidence interval, 99% to 106%) based on C(max), and 107% (90 confidence interval, 105% to 110%) based on area under the concentration versus time curve from zero to infinity (AUC(inf)) values. Mean terminal elimination half-life (t( 1/2 )), steady-state volume of distribution (V(ss)), and total systemic clearance (CL) values of etoposide were approximately 7 hours, 7 L/m2, and 17 mL/min/m2 after Etopophos and VePesid treatments, respectively. The main toxicity observed was myelosuppression, characterized by leukopenia and neutropenia. Conclusion: With respect to plasma levels of etoposide, IV Etopophos is bioequivalent to IV VePesid.

Original languageEnglish (US)
Pages (from-to)2835-2841
Number of pages7
JournalJournal of Clinical Oncology
Volume13
Issue number11
StatePublished - Nov 1995

Fingerprint

Therapeutic Equivalency
Etoposide
Intravenous Administration
Pharmacokinetics
Neoplasms
etoposide phosphate
Area Under Curve
Confidence Intervals
Leukopenia
Prodrugs
Neutropenia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kaul, S., Igwemezie, L. N., Stewart, D. J., Fields, S. Z., Kosty, M., Levithan, N., ... Barbhaiya, R. H. (1995). Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. Journal of Clinical Oncology, 13(11), 2835-2841.

Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. / Kaul, Sanjeev; Igwemezie, Linus N.; Stewart, David J.; Fields, Scott Z.; Kosty, Michael; Levithan, Nathan; Bukowski, Ronald; Gandara, David; Goss, Glenwood; O'Dwyer, Peter; Schacter, Lee P.; Barbhaiya, Rashmi H.

In: Journal of Clinical Oncology, Vol. 13, No. 11, 11.1995, p. 2835-2841.

Research output: Contribution to journalArticle

Kaul, S, Igwemezie, LN, Stewart, DJ, Fields, SZ, Kosty, M, Levithan, N, Bukowski, R, Gandara, D, Goss, G, O'Dwyer, P, Schacter, LP & Barbhaiya, RH 1995, 'Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors', Journal of Clinical Oncology, vol. 13, no. 11, pp. 2835-2841.
Kaul, Sanjeev ; Igwemezie, Linus N. ; Stewart, David J. ; Fields, Scott Z. ; Kosty, Michael ; Levithan, Nathan ; Bukowski, Ronald ; Gandara, David ; Goss, Glenwood ; O'Dwyer, Peter ; Schacter, Lee P. ; Barbhaiya, Rashmi H. / Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 11. pp. 2835-2841.
@article{2d881219a6aa45aa8bbb3eaf11e28570,
title = "Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors",
abstract = "Purpose: To assess the pharmacokinetics and bioequivalence of etoposide following intravenous (IV) administration of etoposide phosphate (Etopophos; Bristol-Myers Squibb, Princeton, NJ), a prodrug of etoposide, and VePesid (Bristol-Myers Squibb). Patients and Methods: Forty-nine solid tumor patients were randomized to receive Etopophos or VePesid on day 1 of a day-1,3,5 schedule of treatment. The alternate drug was given on day 3 and repeated on day 5. The dose, 150 mg/m2 of etoposide equivalent, was administered by constant rate infusion over 3.5 hours. The plasma concentrations of etoposide phosphate and etoposide were determined using validated high-performance liquid chromatography (HPLC) assays. Pharmacokinetic parameters were calculated by a noncompartmental method. Etopophos was considered ta be bioequivalent to VePesid if the 90{\%} confidence limits for the differences in mean maximum concentration (C(max)) and AUC(inf) of etoposide were contained within 80{\%} to 125{\%} for the log-transformed data. Results: Forty-one patients were assessable for pharmacokinetics and bioequivalence assessment. Following IV administration, etoposide phosphate was rapidly and extensively converted to etoposide in systemic circulation, resulting in insufficient data to estimate its pharmacokinetics. The mean bioavailability of etoposide from Etopophos, relative to VePesid, was 103{\%} (90{\%} confidence interval, 99{\%} to 106{\%}) based on C(max), and 107{\%} (90 confidence interval, 105{\%} to 110{\%}) based on area under the concentration versus time curve from zero to infinity (AUC(inf)) values. Mean terminal elimination half-life (t( 1/2 )), steady-state volume of distribution (V(ss)), and total systemic clearance (CL) values of etoposide were approximately 7 hours, 7 L/m2, and 17 mL/min/m2 after Etopophos and VePesid treatments, respectively. The main toxicity observed was myelosuppression, characterized by leukopenia and neutropenia. Conclusion: With respect to plasma levels of etoposide, IV Etopophos is bioequivalent to IV VePesid.",
author = "Sanjeev Kaul and Igwemezie, {Linus N.} and Stewart, {David J.} and Fields, {Scott Z.} and Michael Kosty and Nathan Levithan and Ronald Bukowski and David Gandara and Glenwood Goss and Peter O'Dwyer and Schacter, {Lee P.} and Barbhaiya, {Rashmi H.}",
year = "1995",
month = "11",
language = "English (US)",
volume = "13",
pages = "2835--2841",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors

AU - Kaul, Sanjeev

AU - Igwemezie, Linus N.

AU - Stewart, David J.

AU - Fields, Scott Z.

AU - Kosty, Michael

AU - Levithan, Nathan

AU - Bukowski, Ronald

AU - Gandara, David

AU - Goss, Glenwood

AU - O'Dwyer, Peter

AU - Schacter, Lee P.

AU - Barbhaiya, Rashmi H.

PY - 1995/11

Y1 - 1995/11

N2 - Purpose: To assess the pharmacokinetics and bioequivalence of etoposide following intravenous (IV) administration of etoposide phosphate (Etopophos; Bristol-Myers Squibb, Princeton, NJ), a prodrug of etoposide, and VePesid (Bristol-Myers Squibb). Patients and Methods: Forty-nine solid tumor patients were randomized to receive Etopophos or VePesid on day 1 of a day-1,3,5 schedule of treatment. The alternate drug was given on day 3 and repeated on day 5. The dose, 150 mg/m2 of etoposide equivalent, was administered by constant rate infusion over 3.5 hours. The plasma concentrations of etoposide phosphate and etoposide were determined using validated high-performance liquid chromatography (HPLC) assays. Pharmacokinetic parameters were calculated by a noncompartmental method. Etopophos was considered ta be bioequivalent to VePesid if the 90% confidence limits for the differences in mean maximum concentration (C(max)) and AUC(inf) of etoposide were contained within 80% to 125% for the log-transformed data. Results: Forty-one patients were assessable for pharmacokinetics and bioequivalence assessment. Following IV administration, etoposide phosphate was rapidly and extensively converted to etoposide in systemic circulation, resulting in insufficient data to estimate its pharmacokinetics. The mean bioavailability of etoposide from Etopophos, relative to VePesid, was 103% (90% confidence interval, 99% to 106%) based on C(max), and 107% (90 confidence interval, 105% to 110%) based on area under the concentration versus time curve from zero to infinity (AUC(inf)) values. Mean terminal elimination half-life (t( 1/2 )), steady-state volume of distribution (V(ss)), and total systemic clearance (CL) values of etoposide were approximately 7 hours, 7 L/m2, and 17 mL/min/m2 after Etopophos and VePesid treatments, respectively. The main toxicity observed was myelosuppression, characterized by leukopenia and neutropenia. Conclusion: With respect to plasma levels of etoposide, IV Etopophos is bioequivalent to IV VePesid.

AB - Purpose: To assess the pharmacokinetics and bioequivalence of etoposide following intravenous (IV) administration of etoposide phosphate (Etopophos; Bristol-Myers Squibb, Princeton, NJ), a prodrug of etoposide, and VePesid (Bristol-Myers Squibb). Patients and Methods: Forty-nine solid tumor patients were randomized to receive Etopophos or VePesid on day 1 of a day-1,3,5 schedule of treatment. The alternate drug was given on day 3 and repeated on day 5. The dose, 150 mg/m2 of etoposide equivalent, was administered by constant rate infusion over 3.5 hours. The plasma concentrations of etoposide phosphate and etoposide were determined using validated high-performance liquid chromatography (HPLC) assays. Pharmacokinetic parameters were calculated by a noncompartmental method. Etopophos was considered ta be bioequivalent to VePesid if the 90% confidence limits for the differences in mean maximum concentration (C(max)) and AUC(inf) of etoposide were contained within 80% to 125% for the log-transformed data. Results: Forty-one patients were assessable for pharmacokinetics and bioequivalence assessment. Following IV administration, etoposide phosphate was rapidly and extensively converted to etoposide in systemic circulation, resulting in insufficient data to estimate its pharmacokinetics. The mean bioavailability of etoposide from Etopophos, relative to VePesid, was 103% (90% confidence interval, 99% to 106%) based on C(max), and 107% (90 confidence interval, 105% to 110%) based on area under the concentration versus time curve from zero to infinity (AUC(inf)) values. Mean terminal elimination half-life (t( 1/2 )), steady-state volume of distribution (V(ss)), and total systemic clearance (CL) values of etoposide were approximately 7 hours, 7 L/m2, and 17 mL/min/m2 after Etopophos and VePesid treatments, respectively. The main toxicity observed was myelosuppression, characterized by leukopenia and neutropenia. Conclusion: With respect to plasma levels of etoposide, IV Etopophos is bioequivalent to IV VePesid.

UR - http://www.scopus.com/inward/record.url?scp=0028871358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028871358&partnerID=8YFLogxK

M3 - Article

C2 - 7595746

AN - SCOPUS:0028871358

VL - 13

SP - 2835

EP - 2841

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -